JAZZ · Jazz Pharmaceuticals plc · Share Buybacks
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| — | $500,000,000 | $225,000,000 | 2025-06-30 | — | 8-K , filed 2026-11-02 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-09-30 YTD | $225,000,000 | 10-Q, filed 2026-11-02 | ||
| 2025-12-31 | $125,023,000 | 10-K, filed 2026-02-24 | ||
| 2024-12-31 | $311,429,000 | 10-K, filed 2026-02-24 | ||
| 2023-12-31 | $269,761,000 | 10-K, filed 2026-02-24 | ||
| 2022-12-31 | $54,000 | 10-K, filed 2025-02-26 | ||
| 2021-12-31 | $0 | 10-K, filed 2024-02-28 | ||
| 2020-12-31 | $146,537,000 | 10-K, filed 2023-03-01 | ||
| 2019-12-31 | $301,450,000 | 10-K, filed 2022-03-01 | ||
| 2018-12-31 | $523,672,000 | 10-K, filed 2021-02-23 | ||
| 2017-12-31 | $98,799,000 | 10-K, filed 2020-02-25 | ||
| 2016-12-31 | $278,296,000 | 10-K, filed 2019-02-26 | ||
| 2015-12-31 | $61,553,000 | 10-K, filed 2018-02-27 | ||
| 2014-12-31 | $42,215,000 | 10-K, filed 2017-02-28 | ||
| 2013-12-31 | $136,484,000 | 10-K, filed 2016-02-23 | ||